The British journal of nutrition

Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease.

PMID 25181575


Although epidemiological findings support a role for vitamin K status in the improvement of bone indices in adult patients with Crohn's disease (CD), this needs to be confirmed in double-blind, randomised controlled trials (RCT) with phylloquinone (vitamin K1). By conducting two RCT, the present study aimed to first establish whether supplementation with 1000xa0μg of phylloquinone daily near-maximally suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on the indices of bone turnover and bone mass. The initial dose-ranging RCT was conducted in adult patients with CD (n 10 per group) using 0 (placebo), 1000 or 2000xa0μg of phylloquinone daily for 2 weeks. In the main RCT, the effect of placebo v. 1000xa0μg vitamin K/d (both co-administered with Ca (500xa0mg/d) and vitamin D3 (10xa0μg/d)) for 12 months (n 43 per group) on the biochemical indices of bone turnover (determined by enzyme immunoassay) and bone mass (determined by dual-energy X-ray absorptiometry) were investigated. At baseline, the mean %ucOC was 47xa0%, and this was suppressed upon supplementation with 1000 μg of phylloquinone daily (xa0-xa081xa0%; P0·1) on bone turnover markers or on the bone mass of the lumbar spine or femur, but modestly increased (P